|
17 Sep 2025 |
Cipla
|
Consensus Share Price Target
|
1559.60 |
1676.69 |
- |
7.51 |
buy
|
|
|
|
|
28 Jul 2024
|
Cipla
|
Prabhudas Lilladhar
|
1559.60
|
1680.00
|
1575.00
(-0.98%)
|
Target met |
Accumulate
|
|
|
|
|
26 Jul 2024
|
Cipla
|
Motilal Oswal
|
1559.60
|
1830.00
|
1575.00
(-0.98%)
|
|
Buy
|
|
|
Cipla delivered in-line 1QFY25 performance. It continued to track well in the US generics segment, with sales scaling an all-time quarterly high of USD250m.
|
|
26 Jun 2024
|
Cipla
|
Motilal Oswal
|
1559.60
|
1700.00
|
1479.10
(5.44%)
|
Target met |
Buy
|
|
|
Considering a healthy pipeline of niche products and superior execution in the branded generics segment, we value Cipla on SOTP basis (24x 12M forward earnings and NPV of INR30 for g-Revlimid) to arrive at our TP of INR1,700. We maintain BUY rating on the stock.
|
|
14 Jun 2024
|
Cipla
|
BOB Capital Markets Ltd.
|
1559.60
|
1560.00
|
1564.75
(-0.33%)
|
Target met |
Hold
|
|
|
Strong traction in North America business and consistent performance in One-India; South Africa and Global Access business stabilising
|
|
24 May 2024
|
Cipla
|
FundsIndia
|
1559.60
|
1776.00
|
1486.45
(4.92%)
|
|
Buy
|
|
|
|
|
24 May 2024
|
Cipla
|
Geojit BNP Paribas
|
1559.60
|
1685.00
|
1486.45
(4.92%)
|
Target met |
Buy
|
|
|
|
|
13 May 2024
|
Cipla
|
ICICI Direct
|
1559.60
|
1645.00
|
1414.65
(10.25%)
|
Target met |
Buy
|
|
|
|
|
13 May 2024
|
Cipla
|
SMC online
|
1559.60
|
|
1414.65
(10.25%)
|
|
Results Update
|
|
|
|
|
13 May 2024
|
Cipla
|
Axis Direct
|
1559.60
|
1550.00
|
1414.65
(10.25%)
|
Target met |
Buy
|
|
|
We have BUY on the stock
|
|
14 Mar 2024
|
Cipla
|
Sharekhan
|
1559.60
|
1700.00
|
1488.45
(4.78%)
|
Target met |
Buy
|
|
|
|